52-week adjusted-price high
ActiveAdjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.
Over 5 occurrences, 20-day forward avg gained 7.23%, beat the market by 5.18 pts; win rate 40%.
Free trial
Analyze this stock with AI
Ask AI to research recent events and build a visual report.
Tell your AI:
“Help me set up FinLab and analyze OSCR Oscar Health, Inc.: https://finlab.finance/en/setup?stock=OSCR”
OSCR
Oscar Health, Inc. Healthcare As of 2026-06-18
Quality Weak
Valuation Cheaper
Risk High vol
Active signals Active 52-week adjusted-price high Top-quintile 6-month momentum Filed revenue acceleration
28.4 Close (USD)
+136.08% 60-day
- Quality is weaker than peers. Operating margin is only around the 36th percentile. TTM ROE is about -2.4%.
- Valuation is cheaper than most peers. TTM P/E is in the 6th percentile, lower than most liquid US common stocks.
- Recent volatility is elevated. 60-day annualized volatility is in the 80th percentile. Average 20-day dollar volume is about $181.8M.
- Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum, Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.
Factor profile
Factor radar Good Valuation
69Valuation
Indicators in this group are ranked by market percentile; lower valuation and volatility are better.
TTM P/E -52.59
Price / book 5.09
Free-cash-flow yield (%) 33.05
Historical evidence
Signals active now
Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.
Top-quintile 6-month momentum
Active · now 89.66101694915254%The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.
Average forward return after Top-quintile 6-month momentum。20-day: Win 54.5%, Sample 11, Median +7.06%, Excess +2.34%, Beat mkt rate 54.5%；60-day: Win 50%, Sample 10, Median +8.24%, Excess +6.27%, Beat mkt rate 50%；120-day: Win 50%, Sample 10, Median -5.67%, Excess +16.61%, Beat mkt rate 30%
120 days after: historical avg +25.99%
20-day +3.45%
60-day +11.86%
120-day +25.99%
20-day
60-day
120-day
Win
54.5%
50%
50%
Sample
11
10
10
Median
+7.06%
+8.24%
-5.67%
Excess
+2.34%
+6.27%
+16.61%
Beat mkt rate
54.5%
50%
30%
Over 10 occurrences, 120-day forward avg gained 25.99%, beat the market by 16.61 pts; win rate 50%.
Filed revenue acceleration
Active · now 31.9479142137467%TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.
Over 5 occurrences, 20-day forward avg gained 3.22%, beat the market by 2.38 pts; win rate 60%.
Market-wide momentum baseline
Across 94,737 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.40%, a 58.3% positive-return rate, and +3.10 percentage points of average excess return versus the S&P 500.
Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).
Signals not active now
Inactive signals still show the stock-specific historical forward-return distribution for context.
EPS surprise beat
PendingReported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.
11 times historically; 60-day forward avg +3.77%, win rate 60%, beating the market by +1.56 pts on average.
Free trial
Analyze this stock with AI
Ask AI to research recent events and build a visual report.
Tell your AI:
“Help me set up FinLab and analyze OSCR Oscar Health, Inc.: https://finlab.finance/en/setup?stock=OSCR”
Method and limits
- Returns use us_price:adj_close, adjusted for splits and dividends where available.
- Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
- Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
- The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
- Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
- Overlapping event windows are descriptive distributions, not independent samples.
This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.